The Three-Fold Axis of the HIV-1 Capsid Lattice Is the Species-Specific Binding Interface for TRIM5α

Damien Morger,* Franziska Zosel,* Martin Bühlmann,* Sara Züger,* Maximilian Mittelviefhaus,* Benjamin Schuler,* Jeremy Luban,b Markus G. Grütter*a

A Department of Biochemistry, University of Zurich, Zurich, Switzerland
b Program in Molecular Medicine and Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts, USA

ABSTRACT Rhesus TRIM5α (rhTRIM5α) potently restricts replication of human immunodeficiency virus type 1 (HIV-1). Restriction is mediated through direct binding of the C-terminal B30.2 domain of TRIM5α to the assembled HIV-1 capsid core. This host-pathogen interaction involves multiple capsid molecules within the hexagonal HIV-1 capsid lattice. However, the molecular details of this interaction and the precise site at which the B30.2 domain binds remain largely unknown. The human orthologue of TRIM5α (hsTRIM5α) fails to block infection by HIV-1 both in vivo and in vitro. This is thought to be due to differences in binding to the capsid lattice. To map the species-specific binding surface on the HIV-1 capsid lattice, we used microscale thermophoresis and dual-focus fluorescence correlation spectroscopy to measure binding affinity of rhesus and human TRIM5α B30.2 domains to a series of HIV-1 capsid variants that mimic distinct capsid arrangements at each of the symmetry axes of the HIV-1 capsid lattice. These surrogates include previously characterized capsid oligomers, as well as a novel chemically cross-linked capsid trimer that contains cysteine substitutions near the 3-fold axis of symmetry. The results demonstrate that TRIM5α binding involves multiple capsid molecules along the 2-fold and 3-fold interfaces between hexamers and indicate that the binding interface at the 3-fold axis contributes to the well-established differences in restriction potency between TRIM5α orthologues.

IMPORTANCE TRIM5α is a cellular protein that fends off infection by retroviruses through binding to the viruses’ protein shell surrounding its genetic material. This shell is composed of several hundred capsid proteins arranged in a honeycomb-like hexagonal pattern that is conserved across retroviruses. By binding to the complex lattice formed by multiple capsid proteins, rather than to a single capsid monomer, TRIM5α restriction activity persists despite the high mutation rate in retroviruses such as HIV-1. In rhesus monkeys, but not in humans, TRIM5α confers resistance to HIV-1. By measuring the binding of human and rhesus TRIM5α to a series of engineered HIV-1 capsid mimics of distinct capsid lattice interfaces, we reveal the HIV-1 capsid surface critical for species-specific binding by TRIM5α.

KEYWORDS B30.2, CypA, HIV-1, TRIM5, TRIM5α, affinity, binding, capsid, interaction, species specificity

The family of tripartite motif-containing (TRIM) proteins encompasses nearly 100 members, many of which play important roles in innate immunity and have antiviral activity. Of the approximately 20 TRIMs identified to inhibit retroviral infectivity, TRIM5α imposes the most potent block to retroviral infection (1). The discovery of TRIM5α as the main restriction factor responsible for the HIV-1 resistance in rhesus macaques (rhTRIM5α) has prompted intensive research efforts, making TRIM5 one of
the best-studied TRIMs (2, 3). Many of the functional aspects of how TRIM5 acts to confer resistance to retroviruses can be attributed to its multidomain composition, characteristic of the tripartite/RBCC motif: an N-terminal RING domain, followed by a B-box2 domain and a coiled-coil domain (4). The RING domain confers E3 ubiquitin ligase activity (5), the B-box2 domain mediates self-association important for higher-order oligomerization (6–8), and the coiled-coil domain causes TRIM to form stable dimers (9–14).

At the C terminus, TRIM5α contains an additional B30.2 domain. This domain specifically recognizes retroviral capsids and defines the restriction specificity (15, 16). Recognition by TRIM5α occurs immediately upon exposure of the retrovirus core to the target cell cytoplasm at the early postentry stage of retroviral infection (2, 3). The interaction of the B30.2 domain with the capsid is weak but is potentiated through avidity effects due to dimerization and higher-order oligomerization of TRIM5α into a hexagonal lattice that is complementary to the hexagonal arrangement of retroviral capsids, ideally aligning arrays of B30.2 domains to interact with the repeating binding sites on the capsid surface (6–8, 17–19). By its specificity for the common hexagonal lattice pattern of retroviral capsids, TRIM5α can recognize a broad range of retroviral cores of highly variable primary structures (11, 20–27). This allows TRIM5α to remain restrictive despite the high mutation rate of retroviruses. However, the structural basis for capsid recognition at the crucial step of binding remains elusive.

In TRIM5α, the determinants for restriction specificity are located on four variable loops, v1 to v4, on the surface of the B30.2 domain. Single nucleotide polymorphisms within v1 to v4 can change the restriction specificities of TRIM5α between different primate populations or species. Unlike some nonhuman primate orthologues, human TRIM5α (hsTRIM5α) only weakly inhibits HIV-1 infection but potently restricts N-tropic murine leukemia virus (N-MLV) instead (21, 22). A single amino acid substitution from arginine to proline at position 332 of hsTRIM5α is sufficient to confer the ability to restrict HIV-1 (28). In some primate species, the B30.2 domain has been replaced by cyclophilin A (CypA), which binds to the HIV-1 capsid protein via an exposed proline-rich loop that overlaps with the predicted binding surface of the B30.2 domain (3, 29–33).

Restriction activity of TRIM5α can be blocked in cells by saturation with virus-like particles bearing properly assembled capsid lattices, but free capsid protein does not saturate restriction activity in any context (15). This is because significant binding of TRIM5α is detected only with assembled retroviral capsid lattices: TRIM5α has been shown to associate with capsid cores of virions that have their lipid membrane stripped off by detergents and in vitro-assembled capsids (8, 9, 15, 18, 19). In contrast, the interaction with soluble monomeric or dimeric capsid proteins is very weak: the dissociation constant (K_d) of the rhesus TRIM5α B30.2 domain to a monomeric HIV-1 capsid protein has been estimated to be around 0.4 to 0.5 mM (29, 34). The specific sensing of a conserved lattice pattern is noteworthy, as TRIM5α tolerates not only large variations in capsid sequence but also large differences in the shape of the assembled capsid: TRIM5α binds both spherical (e.g., N-MLV) and conical (e.g., HIV-1) virions, as well as in vitro assemblies of capsid or capsid-nucleocapsid forming cylindrical tubes or even planar two-dimensional lattices (8, 9, 15, 18, 19, 22). The differences in surface curvature present in those capsid structures are accommodated by changes in the interhexamer spacing of the capsid lattice, while the hexameric and pentameric building blocks remain rigid (35). Therefore, it seems surprising that no dramatic increase in binding affinity was reported for isolated capsid hexamers relative to other capsid oligomers (34).

Although oligomerization through the B-box and coiled-coil domains greatly contributes to the binding affinity of TRIM5α, the monomeric B30.2 domain alone is sufficient to detectably bind to assembled capsid tubes (34). Atomic resolution structures of the TRIM5α B30.2 domain reveal that the predicted capsid-binding surface formed by the variable loops v1 to v4 is larger than the surface presented by one capsid
subunit in the capsid lattice and suggest that the B30.2 domain binds to a surface area composed of multiple capsid subunits (34, 36).

In order to identify the binding site of rhTRIM5α/H9251 on the HIV-1 capsid lattice, we measured the binding affinity of the TRIM5α B30.2 domain to several isolated capsid oligomers. Each oligomer mimics a specific high-symmetry capsid arrangement present in the hexagonal lattice, as we reasoned that B30.2 binding to these sites will allow the assembly of the complementary hexagonal TRIM5α lattice. We produced the full-length HIV-1 capsid protein, which forms dimers in solution, the monomeric capsid N-terminal domain (NTD), and a disulfide-stabilized hexameric capsid (37–39). To complete the collection of isolated HIV-1 capsid lattice mimics, we designed mutations that allow cross-linking of the capsid NTDs at the 3-fold lattice interface, available models (described below) of the assembled HIV-1 capsid shell were

RESULTS

Design and production of a trimeric HIV-1 capsid that mimics the 3-fold interface on the HIV-1 capsid lattice. In order to characterize binding of TRIM5α to the retroviral capsid surface, we produced oligomeric HIV-1 capsid molecules that mimic distinct capsid arrangements of the assembled HIV-1 capsid lattice (Fig. 1a): the wild-type, full-length HIV-1 capsid protein which forms dimers in solution (capsid dimer) (37), the monomeric HIV-1 capsid N-terminal domain (NTD) without the C-terminal dimerization domain (CTD) (capsid monomer), the disulfide-stabilized hexameric capsid (capsid hexamer) as described by Pornillos et al. (38), and a trimeric HIV-1 capsid that resembles an arrangement around the 3-fold axis of the capsid lattice (Fig. 1b). The interface at the 3-fold axis is formed by six capsid molecules: three of them form a trimeric contact via the CTDs, and the other three come into proximity at their NTDs. The proximal capsid NTDs form a surface that is accessible to TRIM5 binding, while the capsid CTDs are located on the inside of the HIV-1 capsid core.

To design mutations that allow cross-linking of the capsid NTDs at the 3-fold lattice interface, available models (described below) of the assembled HIV-1 capsid shell were
inspected for residues that come into proximity. These models revealed that residues within α-helix 4 have the closest distance between three adjacent capsid NTDs (Fig. 2a and b). However, according to the most recent model of the mature HIV-1 capsid (35) (PDB entry 3J34), these residues are located roughly 20 Å apart. This is too far for chemical cross-linking with commercially available trifunctional cross-linkers (Fig. 2c). However, this is not the case when the structure of a planar HIV-1 capsid lattice derived from two-dimensional capsid arrays is considered (40). There, the NTDs come closer together at the trimer interface due to the lack of curvature in the 2D lattice (PDB entry 3DIK). Also, TRIM5α is known to bind a broad range of retroviruses harboring different capsid curvatures, including planar hexagonal arrays formed by HIV-1 capsid-nucleocapsid mutants (18). Therefore, we considered the HIV-1 capsid lattice structure derived from planar two-dimensional (2D) capsid crystals a valuable model to design potential TRIM5-binding capsid oligomers. By aligning the crystal structure of the HIV-1 capsid NTD (PDB entry 1AK4) onto the cryo-electron microscopy (cryo-EM)-based 9-Å model of the planar lattice (PDB entry 3DIK) using PyMOL (33, 40), we estimated the
closest distances to be \(\sim 10\,\text{Å}\) for residues R82 and P85 (Fig. 2a and b). This distance matches the requirements for cross-linking three neighboring capsid proteins with the trifunctional cross-linker TMEA \([\text{tris}(2\text{-maleimidoethyl)amine}]\) (Fig. 2c). Residues E75, A78, and E79 along \(\alpha\)-helix 4 were chosen as well for mutation to cysteines (Fig. 2b). Because TMEA cross-linking is performed on the assembled HIV-1 capsid, where all lattice contacts are formed, additional destabilizing mutations were introduced to facilitate subsequent disassembly of the cross-linked capsid lattice. Two sets of mutations, W184A M185A and E180D V181A, were tested to destabilize the dimerization interface in the capsid CTD (38, 41, 42).

To test the ability of these mutants to form the relevant lattice interfaces, recombinant capsid proteins were purified and tested for their ability to assemble \textit{in vitro} by dialysis against 1 M sodium chloride at protein concentrations of 10 mg/ml. All capsid mutants, except for the ones harboring W184A M185A mutations in the CTD region, turned turbid, indicative of capsid assembly. Further analysis of the \textit{in vitro}-assembled HIV-1 capsid variants by negative-staining EM revealed that cysteine mutants without destabilizing mutations formed elongated tubes, as observed for the wild-type capsid protein, while cysteine mutants combined with the destabilizing E180D V181A mutations formed both elongated tubes and planar sheets (Fig. 3a and b). The Fourier transform of negative-staining EM images confirms that these planar sheet structures are hexagonal arrays of assembled capsid molecules (Fig. 3a, inset). As outlined above, the planar geometry brings the introduced cysteines closer together, which increases cross-linking efficiency. Short incubation of the assembled capsid with equimolar concentrations of TMEA and subsequent disassembly yielded capsid oligomers coupled to only one TMEA molecule. Under these conditions, the R82C and P85C mutants with predicted distances of 10 Å cross-linked more efficiently to trimers than the other mutants with more distantly positioned cysteines (Fig. 2d). Separation of assembled capsids and soluble capsid proteins was done by centrifugation. Cross-linked trimers were found only in the pellet fraction, confirming that cross-linking of trimer interfaces occurs only in the hexagonal capsid lattice (Fig. 2d).

Of the R82C and P85C mutants, which cross-linked more efficiently to trimers, we focused on the R82C mutation for further purification and characterization, because modifying P85 in the exposed cyclophilin A binding loop might impair TRIM5\(\alpha\) binding (33). Thorough biophysical characterization of the final TMEA cross-linked product (R82C E180D V181D) purified from cross-linked and then disassembled capsid confirmed that it is a trimer in solution (Fig. 3).

\textbf{Binding affinity of TRIM5\(\alpha\) to the capsid dimer does not correlate with restriction specificity.} To measure binding affinities, we used microscale thermophoresis (MST) and dual-focus fluorescence correlation spectroscopy (2fFCS). The B30.2 domains from TRIM5\(\alpha\) and its TRIM20 homolog were fluorescently labeled and titrated with increasing concentrations of unlabeled capsid molecules (see Fig. 4 for SDS analysis of the purified constructs). For determination of affinities in the micromolar range, fluorescence-based methods have the advantage that one reaction partner can be kept constant at a very low (nanomolar) concentration. Thus, the titration can be described with the simple binding isotherm equation \(f_b = \frac{[\text{capsid}]}{K_d} + [\text{capsid}]\), facilitating the comparison of results \(f_b\) is the fraction of bound B30.2 domain, [capsid] is the capsid concentration, and \(K_d\) is the dissociation constant. All \(K_d\)s reported in this work refer to the concentration of monomeric capsid equivalents to facilitate comparison between the individual values.

By MST, migration of a fluorescently labeled protein is measured along a temperature gradient as a function of a titrated unlabeled binding partner to determine binding affinities. This method is not affected by the increased viscosity at high capsid protein concentrations, as it measures interactions via changes in the equilibrium distribution of the concentration (43). We performed MST measurements with the wild-type HIV-1 capsid dimer and homologous TRIM B30.2 domains. The rhTRIM5\(\alpha\) B30.2 domain has the strongest affinity for the wild-type HIV-1 capsid dimer, in comparison to other capsid molecules reported so far (29). The measurements revealed
The B30.2 domain of TRIM20/pyrin, which has no restriction activity against retroviruses (1), was used as a negative control and exhibited a significantly weaker $K_d$ of 1.8 ± 0.1 mM for the capsid dimer (Fig. 5b).

All measurements were conducted at 280 K because of aggregation of highly concentrated capsid surrogate solutions at higher temperatures. We ruled out a large influence of temperature on the binding affinity by comparing measurements at 280 and 295 K, which yielded very similar $K_d$ of 0.64 ± 0.06 mM at 295 K for binding of the rhTRIM5α B30.2 domain to the capsid dimer (Fig. 6a).
To see if the $K_d$ measured by MST correlate with the species-specific differences in HIV-1 restriction activity, we also measured binding of the capsid dimer to the B30.2 domain of hsTRIM5α/H9251. Unexpectedly, hsTRIM5α/H9251 B30.2 had a slightly higher affinity for the capsid dimer ($K_d = 0.49 \pm 0.06$ mM) than its primate orthologue (Fig. 5b). It thus appears that the binding affinities toward the capsid dimer do not correlate with the in vivo HIV-1 restriction specificities of the two TRIM5α orthologues, suggesting that species specificity is determined by B30.2 binding to other capsid surfaces.

To determine whether capsid dimerization via the CTDs contributes to the affinity for the B30.2 domain, we performed MST measurements with the monomeric capsid NTD (capsid monomer). A very weak $K_d$ of 1.6 ± 0.1 mM was determined for the rhTRIM5α B30.2 domain, which is similar to the $K_d$ of 2.2 ± 0.1 mM obtained for the TRIM20 negative control (Fig. 5a; Table 1). Compared to the binding affinity of 0.62 mM per binding site for the capsid dimer (Fig. 5e; Table 1), the almost 3-fold lower affinity for the capsid monomer confirms the contribution of capsid dimerization to rhTRIM5α B30.2 binding previously reported by nuclear magnetic resonance (NMR) (29). Again, MST measurements of the capsid monomer interaction with hsTRIM5α B30.2 revealed a slightly higher affinity ($K_d$ of 1.1 ± 0.1 mM) than that for the rhesus orthologue (Fig. 5a and f).

To verify these rather low determined affinities and because other capsid surrogates than the capsid monomer and dimer could not be measured by MST, we performed independent measurements of the interaction between the B30.2 domain of rhTRIM5α and the capsid dimer by 2fFCS. With 2fFCS, binding affinities are determined by measuring the diffusion time of a fluorescently labeled protein whose hydrodynamic radius ($R_h$) increases upon binding as a function of the concentration of the unlabeled binding partner (44). Since increasing solution viscosity at high capsid protein concentrations contributes to the binding-dependent change in diffusion time, human cyclophilin A (CypA) was measured as a reference in an independent experiment to correct for viscosity effects as described in Materials and Methods. CypA binds to the capsid surrogates with a much higher affinity ($K_d = 16 \mu$M) (45) than rhTRIM5α, allowing us to separate the contributions of binding and viscosity to the change in $R_h$ (Fig. 7a).
In the absence of capsid protein, we measured an $R_n$ of 3.2 ± 0.1 nm for the rhTRIM5α B30.2 domain, which increases to 5.4 ± 0.1 nm (Fig. 7d) when the capsid dimer is bound. The $K_d$ of this interaction is 0.60 ± 0.07 mM, which matches the $K_d$ obtained by MST (Fig. 6b; Table 1).

**Species specificity of TRIM5α binding to the capsid trimer.** We next probed the interaction of the HIV-1 capsid trimer and hexamer with the TRIM5α B30.2 domains. The capsid hexamer recapitulates capsid interfaces at the 6-fold axis of the hexagonal lattice, and the capsid trimer reflects the common interface between three adjacent hexamers (Fig. 1). Since both capsid oligomers could not be measured to high enough concentrations by MST due to aggregation caused by the temperature gradient, we used 2fFCS as described for the capsid dimer to determine the binding affinities. We obtained $R_n$ values of 5.6 nm and 7 nm for the capsid trimer- and the capsid hexamer-B30.2 complexes, respectively (Fig. 7b to d).
The $K_d$ of the capsid hexamer for the B30.2 domain of rhTRIM5$\alpha$/H9251 was $0.60 \pm 0.09$ mM (Fig. 5d), showing that the capsid hexamer has an increased affinity for the rhTRIM5$\alpha$/H9251 B30.2 domain compared to the monomeric capsid NTD, but not compared to the capsid dimer (Table 1). To investigate if binding to the capsid hexamer accounts for the difference in HIV-1 restriction activity between hsTRIM5$\alpha$/H9251 and rhTRIM5$\alpha$/H9251, we measured the interaction with the B30.2 domain of hsTRIM5$\alpha$/H9251. However, these measurements revealed an affinity of $0.54 \pm 0.1$ mM, which is within error identical to the $K_d$ found for rhTRIM5$\alpha$/H9251 (Fig. 5d and f; Table 1). We note that the data for the capsid hexamer did not perfectly fit the simple one-to-one binding model, as was the case for the other capsid surrogates (Fig. 5d). Possible reasons include the presence of an additional binding mode for the B30.2 domain or further oligomerization of the hexamer at higher concentrations.

Binding of the B30.2 domain of rhTRIM5$\alpha$ to the capsid trimer had a $K_d$ of $0.44 \pm 0.04$ mM (Fig. 5c). Thus, the capsid trimer shows the strongest increase in affinity relative to the monomeric capsid NTD among the capsid surrogates investigated (Table 1; Fig. 5e). In contrast, measurement of the interaction with hsTRIM5$\alpha$/H9251 B30.2 revealed a significantly lower affinity, with a $K_d$ of $0.84 \pm 0.09$ mM for the capsid trimer (Fig. 5c and e; Table 1). The affinity difference of the B30.2 domains of hsTRIM5$\alpha$/H9251 and rhTRIM5$\alpha$/H9251 for the capsid trimer correlates with the species-specific difference in restriction activity.

![FIG 6 rhTRIM5$\alpha$/H9251 B30.2 binding to the capsid dimer measured at different temperatures and with different methods. (a) MST measurements performed at 295 K. Error bars indicate the standard deviation of three independent measurements. Fitting the data with equation 1 (black line) yields a $K_d$ of $0.64 \pm 0.06$ mM, within error of the $K_d$ obtained at 280 K. (a) Overlay of 2FCS and MST measurements at 295 K. The MST data are fitted with equation 1 (solid line); error bars indicate the standard deviation of three independent measurements. For determining the $K_d$ by 2FCS, CypA was used as a reference to correct for viscosity effects at increased capsid protein concentrations (see Materials and Methods). The 2FCS data were converted to fraction bound with equation 3 and are shown with a 1:1 binding isotherm (solid line), calculated using the $K_d$ from a fit with equation 2. MST and 2FCS yield consistent binding curves with $K_d$ values of $0.62 \pm 0.04$ mM (MST) and $0.60 \pm 0.07$ mM (2FCS).](http://jvi.asm.org/)

**TABLE 1** Overview of dissociation constants measured by MST and 2FCS for the interaction of TRIM B30.2 domains and CypA with the different HIV-1 capsid surrogates normalized to monomeric capsid equivalents

| Capsid surrogate or negative control | rhTRIM5$\alpha$/H9251 | hsTRIM5$\alpha$/H9251 | hsTRIM20 | CypA |
|-------------------------------------|-----------------------|-----------------------|----------|------|
| Capsid monomer                      | $1.6 \pm 0.1$ mM$^b$  | $1.1 \pm 0.1$ mM$^b$ | $2.2 \pm 0.1$ mM$^b$ | ND |
| Capsid dimer                        | $0.61 \pm 0.04$ mM$^d$| $0.49 \pm 0.06$ mM$^d$| $1.8 \pm 0.1$ mM$^d$  | $26.5 \pm 5$ $\mu$M$^c$ |
| Capsid trimer                       | $0.44 \pm 0.04$ mM$^d$| $0.84 \pm 0.09$ mM$^c$| ND       | $17.8 \pm 2$ $\mu$M$^c$ |
| Capsid hexamer                      | $0.60 \pm 0.09$ mM$^c$| $0.54 \pm 0.1$ mM$^c$ | ND       | $28.9 \pm 3$ $\mu$M$^c$ |
| Lysozyme                            | $2.6 \pm 0.3$ mM$^c$  | ND        | ND       | ND |

$^a$The $K_d$s for the interactions of TRIM B30.2 domains with the different HIV-1 capsid surrogates, as well as lysozyme, are indicated relative to the concentrations of the monomeric capsid equivalents. The $K_d$s of the rhTRIM5$\alpha$/H9251 and hsTRIM5$\alpha$/H9251 B30.2 domains for the capsid trimer, which has the strongest binding affinity for the B30.2 domain of rhTRIM5$\alpha$/H9251 as well as the greatest increase in affinity compared to the $K_d$s of the B30.2 domain of hsTRIM5$\alpha$/H9251, are highlighted in bold. ND, not determined.

$^b$Average of $K_d$s determined by MST.

$^c$Average of $K_d$s determined by MST and 2FCS.
against HIV-1 and suggests that determinants for species-specific recognition by TRIM5α are located at the 3-fold lattice interface of the HIV-1 capsid.

**DISCUSSION**

The capsid molecules described in this study mimic different surface areas on the assembled HIV-1 capsid core. All together, they represent all high-symmetry capsid arrangements on the hexagonal lattice. To determine the potential binding site of TRIM5α, we measured the binding affinities between these capsid surrogates and the B30.2 domains of rhTRIM5α and hsTRIM5α. A detailed knowledge of this binary interaction is essential for understanding the overall binding capability of TRIM5α to the HIV-1 capsid lattice, but the experimental determination of the very high dissociation constants poses a technical challenge. We measured these low affinities with two fluorescence-based methods, MST and 2fFCS. Thus, we could employ low concentrations of one titrant (the fluorescently labeled B30.2 domains), enabling the use of a first-order binding model to fit the data.

MST measurements revealed a $K_d$ of around 0.6 mM for binding of the rhTRIM5α B30.2 domain to the capsid dimer, which was confirmed by 2fFCS (Fig. 5a). This interaction is clearly distinguishable from the negative controls and the $K_d$ for the capsid monomer (Fig. 5; Table 1). This observation agrees with previous findings from NMR studies: the interaction with the capsid monomer is very weak, and dimerization of the capsid via the CTD greatly enhances the affinity for the B30.2 domain of rhTRIM5α (29, 34). We also found that relative to the capsid monomer, the affinity of the capsid dimer and hexamer for the B30.2 domain of rhTRIM5α is similarly increased ($K_d$ values of 0.62 and 0.60 mM, respectively) (Table 1). Strikingly, the capsid trimer, which has never been investigated before, had the highest affinity for the B30.2 domain of rhTRIM5α, with a $K_d$ of about 0.44 mM per capsid subunit (Fig. 5c and e; Table 1).
In order to investigate if one of these HIV-1 capsid surrogates mimics a lattice surface area that accounts for species-specific restriction by TRIM5α/H9251, we also measured the binding affinities of the hsTRIM5α/H9251 B30.2 domain. We found that the capsid monomer, dimer, and hexamer all had a similar or slightly stronger affinity for the human orthologue (Fig. 5; Table 1). However, the capsid trimer had a significantly weaker affinity for the hsTRIM5α B30.2 domain than its rhesus orthologue (K<sub>d</sub> of 0.44 mM and 0.84 mM, respectively) (Fig. 5c; Table 1). Based on this K<sub>d</sub> difference, we conclude that the capsid trimer harbors the binding surface area that contributes to the species-specific restriction potency of TRIM5α against HIV-1. The 2-fold increase in affinity between monomeric B30.2 domains for the 3-fold capsid lattice interface is expected to be potentiated through avidity effects in the context of HIV-1 restriction in vivo: the weak B30.2-capsid interactions are amplified, as TRIM5α self-assembles into a hexagonal superlattice matching the geometry of the assembled HIV-1 capsid, thereby ideally positioning many B30.2 domains to their repeating binding sites on the HIV-1 capsid lattice (6–9, 11, 18, 19, 36, 46). Therefore, small differences in affinity between different B30.2 domains will be translated into large differences in the overall binding capability of TRIM5α, which could define the restriction potency of the different protein variants. It is possible that the R82C mutation in α-helix 4 of the capsid trimer impairs B30.2 binding by influencing the capsid surface region near the CypA binding loop, explaining the weak affinities determined with the capsid trimer. Nevertheless, CypA binding to the capsid trimer was not weakened compared to the binding to the wild-type capsid dimer (Table 1), and we found that rhesus TRIM5α B30.2 binding to the capsid trimer was not just retained but was even stronger than the affinities measured with the other HIV-1 capsid surrogates.

Our data suggest that TRIM5α binds to an overlapping surface area shared among the capsid dimer, trimer, and hexamer, involving multiple capsid molecules. Such capsid arrangements are found at the interhexamer interfaces of the HIV-1 capsid lattice. Binding of TRIM5α to this region would be in line with the mapping of residues involved in TRIM5α binding to the outer edges of the capsid hexamer (26, 29–32) (Fig. 8a). On the B30.2 domain, capsid binding is predicted to be mediated by four variable loop regions, v1 to v4 (29, 47, 48). Recent atomic resolution structures of the TRIM5α B30.2 domain have shown that these loop regions form a continuous surface, large enough to cover three or four capsid molecules (34, 36). Hot spots of positive selection through primate evolution and residues most affected by capsid binding in NMR studies cluster in the v1 loop of the B30.2 domain of rhTRIM5α (47, 49). Also, the single
arginine-to-proline mutation that switches the restriction activity of hsTRIM5α toward HIV-1 is located on the v1 loop (28). Based on our binding results, we propose a model for the interaction of the B30.2 domain of rhTRIM5α with the HIV-1 capsid lattice that involves these known binding determinants of TRIM5α. The B30.2 v1 loop and the capsid trimmer interface are the dominating determinants for both affinity and specificity in the TRIM5α capsid interaction. Therefore, we suggest that the B30.2 v1 loop region binds near the 3-fold symmetry axis between three adjacent capsid hexamers of the HIV-1 capsid lattice. By positioning the remaining predicted binding surface of the B30.2 domain, involving the v2, v3, and v4 loops, at the 2-fold symmetry axis between two neighboring hexamers, we match the increased affinity observed for all the oligomeric capsids tested, as this interface combines capsid arrangements mimicked by the capsid dimer, trimer, and hexamer (Fig. 8b). A very similar binding model has been predicted by computational docking of the B30.2 domain to the HIV-1 capsid (50).

In the TRIM5 variant TRIMCyp, which confers HIV-1 resistance, for example, in owl monkeys, the C-terminal B30.2 domain has been replaced by a CypA domain (3). A binding model where the CypA domain preferentially binds at the 3-fold symmetry interface of the HIV-1 capsid lattice is also suggested by our data: as for the B30.2 domain of rhTRIM5α, we found that CypA has a higher average binding affinity per capsid subunit for the capsid trimer than for the other capsid molecules (Table 1). This is likely the case because the CypA binding loops on the HIV-1 capsids come together at the 3-fold symmetry axis, while in the dimer and hexamer they are pointing away from each other. Preferential binding of the CypA domain to the 3-fold capsid symmetry interfaces, as we propose for the B30.2 domain of TRIM5α, would allow TRIMCyp to match the same geometrical criteria to bind and form a complementary superlattice on the retroviral capsid as TRIM5α.

In conclusion, we present a novel chemically cross-linked HIV-1 capsid trimer that recapitulates the capsid arrangement at the 3-fold symmetry axis on the outward-facing side of the assembled HIV-1 capsid lattice. Its potential as a tool for characterizing HIV-1 capsid binding molecules is exemplified in this study. The binding measurements with orthologous TRIM5α B30.2 domains reveal that this capsid trimer has a stronger affinity for rhTRIM5α than other capsid oligomers that mimic capsid arrangements on the HIV-1 lattice. Of the monomeric, dimeric, trimeric, and hexameric capsids measured, only the binding affinities of the capsid trimer to the human and rhesus B30.2 domains correlate with their respective HIV-1 restriction activities. Based on our results, we propose a binding model that explains how a single point mutation in the v1 loop of the B30.2 domain is sufficient to confer HIV-1 restriction activity to the otherwise unrestrictive hsTRIM5α.

**MATERIALS AND METHODS**

**Design and production of cross-linked HIV-1 capsid trimers.** The DNA sequence encoding amino acids 133 to 363 of the HIV-1 Gag polyprotein was amplified from psPAX2 (51) and cloned into a pET-20b vector (Invitrogen). Mutations were introduced by QuikChange mutagenesis (Invitrogen) and verified by DNA sequencing (Microsynth). The HIV-1 capsid proteins were expressed and purified as previously described (45), with the addition of 100 mM β-mercaptoethanol (βME) to all buffers. Capsid tubes were assembled in vitro by overnight dialysis at 4°C (52) into assembly buffer (20 mM Tris-HCl, pH 8, 1 M NaCl, 100 mM βME).

For cross-linking of assembled capsid tubes harboring mutations E75C, A78C, E79C, R82C, or P85C in their NTD combined with or without destabilizing E180D V181A mutations in the CTD, the initial assembly buffer was exchanged against cross-linking buffer [20 mM HEPES-HCl, pH 7.2, 1 M NaCl, 0.5 mM Tris(2-carboxyethyl)phosphine (TCEP)] by a two-step dialysis. Chemical cross-linking of neighboring NTDs via the introduced cysteines was performed at a concentration of 10 mg/ml capsid protein by incubation with the trifunctional maleimide cross-linker TMEA (Thermo Scientific) at a 1:1 molar ratio of TMEA to capsid monomer for 5 min on ice, followed by quenching with 10 mM dithiothreitol (DTT). Cross-linking products were analyzed by reducing SDS-PAGE.

For purification, TMEA-cross-linked capsid assemblies were disassembled by dialysis into disassembly buffer (20 mM Tris-HCl, pH 8) at 4°C, and the cross-linking products were separated by size exclusion chromatography on a Hi-Load Superdex 200 26/60 column equilibrated with disassembly buffer. Reinjection of the trimer-containing fractions onto the size exclusion column yielded essentially pure capsid trimers. Protein concentration was determined by UV absorbance using molar extinction coeffi-
Production of the HIV-1 capsid monomer, dimer, and hexamer. For the production of monomeric HIV-1 capsid, the gene sequence encoding amino acids 133 to 278 of the HIV-1 Gag polyprotein, comprising the NTD of HIV-1 capsid, was cloned into a pET20b vector with a C-terminal His$_{6}$ tag, cleavable by 3C protease. His-tagged HIV-1 capsid NTD was expressed as previously described (33) and purified by immobilized-metal affinity chromatography (IMAC) using Protino Ni-nitrilotriacetic acid (Ni-NTA) agarose (Macherey-Nagel). Briefly, E. coli cells expressing His-tagged HIV-1 capsid NTD suspended in lysis buffer (50 mM Tris-HCl, pH 8, 300 mM NaCl, 10 mM imidazole, 1 mM phenylmethylsulfonyl fluoride [PMSF], 10 μg/ml RNase A, 5 μg/ml DNase I) were lysed using an EmulsiFlex C3 homogenizer (Avestin, Canada). The cleared lysate was loaded on an equilibrated Ni-NTA gravity column and washed with 50 mM Tris-HCl (pH 8)–300 mM NaCl–40 mM imidazole, and bound protein was eluted with 50 mM Tris-HCl–50 mM NaCl–300 mM imidazole. The C-terminal His tag was cleaved by the addition of His-tagged 3C protease and dialysis against 50 mM Tris-HCl–10 mM imidazole. Untagged HIV-1 capsid NTD was then separated from the tag and the protease by another IMAC and further purified by size exclusion chromatography on a Hi-Load Superdex 75 26/60 column equilibrated with 20 mM Tris-HCl, pH 8.

The wild-type HIV-1 capsid dimer and the disulfide-linked A14C E45C W184A M185A HIV-1 capsid hexamer were produced according to published procedures (38, 45).

Protein concentrations were determined using ε$_{280}$ values of 24,980 M$^{-1}$cm$^{-1}$, 33,524 M$^{-1}$cm$^{-1}$ and 28,210 M$^{-1}$cm$^{-1}$ for the HIV-1 capsid NTD monomer, the HIV-1 capsid dimer, and the disulfide-linked HIV-1 capsid hexamer, respectively.

**TEM analysis of capsid assemblies.** Aliquots from capsid assemblies were diluted to 0.25 to 0.5 mg/ml and 6-μl samples were incubated on Formvar-coated copper grids for 30 s. The grids were blotted, negatively stained three times on 20-μl drops of 2% uranyl acetate for 10 s, blotted, and air dried. Samples were imaged on a Philips CM 100 transmission electron microscope (TEM) at a magnification of >x13,000.

**ESI-MS of cross-linked capsid trimers.** Nanoelectrospray ionization mass spectrometry (nanoESI-MS) analysis of the samples was performed on a Q-TOF Ultima API mass spectrometer (Micromass, United Kingdom). The solutions were infused through a fused silica capillary (inside diameter [i.d.], 75 μm) at a flow rate of 0.50 μl min$^{-1}$. Electrospray Pico Tips (i.d., 30 μm) were obtained from New Objective (Woburn, MA). Mass spectra were acquired by scanning an m/z range from 500 to 2,500 with a scan duration of 1 s and an ionscans delay of 0.1 s. Spray voltage was set to 2.1 kV, cone voltage to 35 V, RF lens 1 energy to 50 eV, and RF lens 2 energy to 10 eV. Sedimentation velocity measurements were conducted at 30,000 rpm and 4°C using a ProteomeLab XL-1 ultracentrifuge (Beckman Coulter). Data were analyzed with SEDFIT (54).

**Production of recombinant TRIM B30.2 domains.** DNA coding for the B30.2 domains of hsTRIM5α and rhTRIM5α (residues 286 to 493 and 288 to 497, respectively) was cloned into the pFXGST vector using fragment exchange (FX) cloning (55). The pFXGST vector was generated by modification of the MultiBac vector pFBDM (56) multiple cloning site 1 (MCS1) to enable FX cloning in analogy to that described by Weinert et al. (12). Briefly, the SapI restriction site between the transposon element TnR and the ColE1 origin of replication was removed, and an Ndel restriction site was inserted into the MCS1 by QuikChange mutagenesis (Invitrogen). The FX cassette of the pFXGST vector (55) was used as the template (including the coding region for an N-terminal His$_{10}$ tag, followed by glutathione S-transferase [GST] and a 3C cleavage site) and cloned into the modified pFBDM vector using NdeI and XbaI restriction sites. The Ndel restriction site was later removed by QuikChange, yielding the pFXGST vector.

The TRIM B30.2 domains were expressed in SF21 cells using the manufacturer’s protocol (Invitrogen). Cells were harvested after 65 to 72 h of expression at 27°C and lysed in lysis buffer (50 mM Tris-HCl, pH 8, 300 mM NaCl, 10 mM imidazole, DNase I, RNase I, Benzonase, and EDTA-free complete inhibitor cocktail [Roche Diagnostics]) using an EmulsiFlex homogenizer. Lysate was cleared, and the HisGST-tagged TRIM B30.2 domain in the supernatant was purified by gravity-flow IMAC as described above, followed by overnight dialysis (Spectra/Por; 12,000 to 14,000 molecular weight cutoff [MWCO]) in cleavage buffer (50 mM Tris-HCl, pH 8.5, 150 mM NaCl, 0.2 mM TCEP) at 4°C in the presence of a 1:20 (wt/wt) ratio of 3C protease. Cleaved HisGST tag and His-3C protease were removed by reapplying the cleavage buffer (50 mM Tris-HCl, pH 8.5, 150 mM NaCl, 0.2 mM TCEP) at 4°C in the presence of a 1:20 (wt/wt) ratio of 3C protease. Cleaved HisGST tag and His-3C protease were removed by reapplying the sample to Ni-NTA agarose. The flowthrough was collected and concentrated to 2 mg/ml, as determined by UV absorbance using a ε$_{280}$ value of 38,390 M$^{-1}$cm$^{-1}$ or 39,880 M$^{-1}$cm$^{-1}$ for the hsTRIM5α or rhTRIM5α B30.2 domain, respectively.

The B30.2 domain of TRIM20 was prepared as described by Weinert et al. (57) and concentrated to 2 mg/ml (ε$_{280}$ = 32,430 M$^{-1}$cm$^{-1}$).

**Production of recombinant human cyclophilin A.** The human cyclophilin A (CypA) gene was cloned into the p7XCH vector, which encodes a C-terminal 3C cleavage site and a His$_{10}$ tag, using FX cloning. The PCR primers were designed such that a Flag tag is encoded at the N terminus of the CypA gene.

The CypA construct was expressed in E. coli BI21(DE3). Cells were grown in 2× YT medium at 37°C to an optical density at 600 nm (OD$_{600}$) of 0.8, and induction was expressed with 0.5 mM IPTG (isopropyl-β-D-thiogalactopyranoside). Cells were harvested after 4 h of expression and lysed in 50 mM...
Fluorescent labeling of TRIM B30.2 domains and CypA. Purified B30.2 domains and CypA were diazylized (Spectra/Por; 6,000 to 8,000 MWCO) overnight at 4°C in labeling buffer (25 mM sodium carbonate, pH 8.5, 100 mM NaCl, 0.5 mM TCEP). Labeling was carried out on ice in the presence of a 1.2-fold molar ratio of NT-647-NHS (Nanotemper) or Alexa Fluor 488-NHS (Alexa 488; Thermo Scientific) by overnight incubation in the dark. At pH 8.5, labeling of the N-terminal amine (pKa 10.5). Therefore, modification of lysines near the binding interface is avoided at labeling efficiencies below one fluorophore per B30.2 domain. Proteins were separated from free dye by size exclusion chromatography on a Superdex 200 10/300 column. Coupling efficiencies were calculated from the absorbances at 280 nm and 650/488 nm, respectively. The average number of dyes per molecule ranged from 0.3 to 0.45. Tryptic digestion of labeled rhTRIM5α B30.2 and matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS) analysis of fluorescent cleavage products after reversed-phase chromatography revealed a single peak corresponding to the N-terminal B30.2 fragment GPSDMFR coupled to Alexa 488, confirming the N terminus as the major site of coupling.

MST. Twenty-five nanomolar concentrations of labeled B30.2 homologs were titrated with a 2:1 dilution series of the different capsid proteins. The samples were loaded into standard capillaries (NanoTemper Technologies GmbH), sealed with soft wax, and equilibrated by incubation at 7°C for 4 h before the measurement. Microscale thermophoresis (MST) measurements were carried out on a NanoTemper Monolith NT.115 instrument (NanoTemper Technologies GmbH) using 40% LED and 20% laser power with the laser switched on for 30 s, followed by an off period of 5 s. Fifteen or 16 thermophoresis measurements were carried out from three independently prepared dilution series. Samples from each dilution series were recorded twice. The raw data were analyzed using the NanoTemper software to obtain binding curves. $K_d$ was calculated with Prism (GraphPad Software) by fitting the data with a 1:1 binding isotherm equation:

$$f_b = \frac{[\text{capsid}]}{K_d + [\text{capsid}]}$$

(1)

where $f_b$ is the fraction of bound B30.2 domain, [capsid] is the capsid concentration, and $K_d$ is the dissociation constant. The MST experiments were carried out at 7°C, because higher capsid concentrations could be achieved without aggregation. To rule out effects of temperature on the binding affinity, measurements at 7°C and room temperature were compared, and very similar affinities were obtained (Fig. 5a).

2FFCS. For dual-focus fluorescence correlation spectroscopy (2FFCS) measurements (44), a capsid dilution series such as that described for MST was prepared with Alexa 488-labeled TRIM5α B30.2 and CypA at a final concentration of labeled protein of 2 nM. CypA was included as a reference to quantify the contribution of viscosity to the measured diffusivity. CypA is suitable as a reference for several reasons. First, it has a similar molecular mass (19 kDa for Flag-CypA) and shape as rhTRIM5α B30.2 (23 kDa) and therefore a similar hydrodynamic radius ($R_h$). Second, CypA and the B30.2 domain occupy overlapping binding surfaces on the capsid (26, 29–33), so their respective capsid complexes should also have similar $R_h$ values. Third, CypA has a relatively high affinity for the HIV-1 capsid surrogates (see Table 1), so binding occurs in a concentration range that is well separated from viscosity effects, which start to interfere with the measurements at capsid concentrations above ~100 μM (Fig. 7). After completion of the 2FFCS measurement, the capsid concentration in each sample was determined via absorbance at 280 nm.

The measurements were carried out at 7°C on a confocal single-molecule instrument (MT200; PicoQuant), equipped with a differential interference contrast prism (U-DICTHC; Olympus). The sample was excited alternatingly with two orthogonally polarized diode lasers at 485 nm (LDH-D-C-485; PicoQuant) with a repetition rate of 40 MHz and a laser power of 30 μW each. The distance, $d$, of 436 ± 10 nm between the two foci in aqueous solution was determined by measuring a series of reference samples with a known diffusion coefficient (58). A custom-built temperature-controlled sample holder was used to cool the sample cell. The microscope objective was cooled as well to minimize the temperature gradient between sample cell and objective.

The fluorescence intensity cross- and autocorrelation curves obtained from the data of each focus were analyzed using a custom-written C++ routine and Mathemtica (Wolfram Research) to obtain diffusion coefficients, $D$ (59). These were converted to hydrodynamic radii, $R_h$, with the Stokes-Einstein relation $R_h = k_BT/(6πηD)$, where $k_B$ is the Boltzmann constant, $T$ is the temperature, and $η$ is the viscosity of the solution. The increase in apparent $R_h$ of the labeled molecules upon binding to capsid was analyzed with a simple stoichiometric binding model multiplied with a correction term for the increased viscosity at high capsid concentrations.

$$R_h = R_{h0} + \left( R_{h0} - R_{h0} \right) \cdot \frac{[\text{capsid}]}{K_d + [\text{capsid}]} \cdot \frac{\eta_{\text{capsid}}}{\eta_0}$$

(2)
In a first step, the CypA data set was fitted to extract the hydrodynamic radius of the unbound molecule \(R_{h,0}\), the hydrodynamic radius of the capsid-CypA complex \(R_{h,unbound}\), and the dissociation constant \(K_d\). The binding of capsid to CypA is largely saturated before the sample viscosity starts to increase significantly, so the contributions of binding and viscosity to the increase in \(R_g\) can be separated (Fig. 7a to c). For fitting the TRIM35α B30.2 2FCS data, the parameters \(R_{h,0}\), \(K_d\), and \(\eta_{buffer}\) were empirically approximated by \(\eta_{buffer} = \eta_0 (1 + [\text{capsid}]^p)\), with \(\eta_0\) being the buffer viscosity, \(\beta\) adjusted in the range of 1.5 to 2 to fit the data, and \([\text{capsid}]\) in \(\mu\text{M}\). The binding of capsid to CypA can be separated (Fig. 7a to c) and the capsid concentration-dependent viscosity contribution \(\eta_{buffer}\) in microscale thermophoresis measurements. We thank Leonardo Scapozza (University of Geneva, Switzerland) for providing access to the Nanotemper Monolith NT.115 instrument for microscale thermophoresis measurements. We also thank Cristina Paulino for assistance with electron microscopy and Daniel Nettels for help with data analysis, instrumentation, and helpful discussions.

We are grateful to Serge Chesnov, Peter Hunziker, and Jolanda Joho-Auchli of the Functional Genomics Center Zurich for protein analysis by mass spectrometry. We thank Leonardo Scapozza (University of Geneva, Switzerland) for providing access to the Nanotemper Monolith NT.115 instrument for microscale thermophoresis measurements. We also thank Cristina Paulino for assistance with electron microscopy and Daniel Nettels for help with data analysis, instrumentation, and helpful discussions.

ACKNOWLEDGMENTS

We thank Leonardo Scapozza (University of Geneva, Switzerland) for providing access to the Nanotemper Monolith NT.115 instrument for microscale thermophoresis measurements. We also thank Cristina Paulino for assistance with electron microscopy and Daniel Nettels for help with data analysis, instrumentation, and helpful discussions. We are grateful to Serge Chesnov, Peter Hunziker, and Jolanda Joho-Auchli of the Functional Genomics Center Zurich for protein analysis by mass spectrometry.

This research was supported by Swiss National Science Foundation grants 310300_122342 and 310308_138673 to M.G.G. and by NIH grants DP1DA034990 and R01AI111809 to J.L.

REFERENCES

1. Uchil PD, Quinlan BD, Chan WT, Luna JM, Mothes W. 2008. TRIM E3 ligases interfere with early and late stages of the retroviral life cycle. PLoS Pathog 4:e16. https://doi.org/10.1371/journal.ppat.0040016.
2. Stremlau M, Owens CM, Perron MJ, Kisselings M, Autissier P, Sodroski J. 2004. The cytoplasmic body component TRIM35α restricts HIV-1 infection in Old World monkeys. Nature 427:848–853. https://doi.org/10.1038/nature02343.
3. Sayah DM, Sokoloska E, Berthoux L, Luban J. 2004. Cyclophilin A retrotransposition into TRIM35 explains owl monkey resistance to HIV-1. Nature 430:569–573. https://doi.org/10.1038/nature02777.
4. Grutter MG, Luban J. 2012. TRIM35 structure, HIV-1 capsid recognition, and innate immune signaling. Curr Opin Virol 2:142–150. https://doi.org/10.1016/j.coiviro.2012.04.003.
5. Diaz-Griffero F, Li X, Javanbakht H, Song B, Welikala S, Stremlau M, Sodroski J. 2006. Rapid turnover and polyubiquitylation of the retroviral restriction factor TRIM35. Virology 349:300–315. https://doi.org/10.1016/j.virology.2005.12.040.
6. Li X, Sodroski J. 2008. The TRIM35α B-box 2 domain promotes cooperative binding to the retroviral capsid by mediating higher-order self-association. J Virol 82:11495–11502. https://doi.org/10.1128/JVI.01548.08.
7. Diaz-Griffero F, Qin KR, Hayashi F, Kigawa T, Finzi A, Sarnak Z, Lienaf M, Yokoyama S, Sodroski J. 2009. A B-box 2 surface patch important for restriction factor TRIM5α self-association, capsid binding avidity, and retrovirus restriction. J Virol 83:10737–10751. https://doi.org/10.1128/JVI.01307-09.
8. Wagner JM, Roganowicz MD, Skorupka K, Alam SL, Christensen D, Doss G, Wan Y, Frank GA, Ganser-Pornillos BK, Sundquist WI, Pornillos O. 2016. Mechanism of B-box 2 domain-mediated higher-order assembly of the retroviral restriction factor TRIM5α. eLife 5:e16309.
9. Langelier CR, Sandrin V, Eckert DM, Christensen DE, Chandrasekaran V, Alam SL, Aiken C, Olsen JC, Kar AK, Sodroski JG, Sundquist WI, Pornillos O. 2016. Biochemical characterization of a recombinant TRIM5α protein that restricts human immunodeficiency virus type 1 replication. J Virol 82:11682–11694. https://doi.org/10.1128/JVI.01562-08.
10. Pertel T, Hausmann S, Morger D, Züger S, Guerra J, Lascano J, Reinhard C, Santoni FA, Uchil PD, Chatel L, Bisiaux A, Albert ML, Strambos-DeCastilla C, Mothes W, Pizzato M, Grutter MG, Luban J. 2011. TRIM5α is an innate immune sensor for the retrovirus capsid lattice. Nature 472:361–366. https://doi.org/10.1038/nature09976.
11. Zhao G, Ke D, Vu T, Ahn J, Shah VB, Yang R, Aiken C, Charlton LM, Gronenborn AM, Zhang P. 2011. Rhesus TRIM5α disrupts the HIV-1 capsid at the inter-hexamer interfaces. PLoS Pathog 7:e1002009. https://doi.org/10.1371/journal.ppat.1002009.
12. Weinert C, Morger D, Djekic A, Grutter MG, Mittl PR. 2015. Crystal structure of TRIM20 C-terminal coiled-coil/B30.2 fragment: implications for the recognition of higher order oligomers. Sci Rep 5:10819. https://doi.org/10.1038/srep10819.
13. Sanchez JG, Okreglicka K, Chandrasekaran V, Welikala S, Sundquist WI, Pornillos O. 2014. The tripartite motif coiled-coil is an elongated antiparallel hairpin dimer. Proc Natl Acad Sci U S A 111:2494–2499. https://doi.org/10.1073/pnas.1318962111.
14. Goldstone DC, Walker PA, Calder LJ, Coombs PJ, Kirkpatrick J, Ball NJ, Hilditch L, Yap MW, Rosenthal PB, Stone JP, Taylor IA. 2014. Structural studies of postentry restriction factors reveal antiparallel dimers that enable avid binding to the HIV-1 capsid lattice. Proc Natl Acad Sci U S A 111:9609–9614. https://doi.org/10.1073/pnas.1402481111.
15. Sebastian S, Luban J. 2005. TRIM35α selectively binds a restriction-sensitive retroviral capsid. Retrovirology 2:40. https://doi.org/10.1186/1742-4690-2-40.
16. Stremlau M, Perron M, Welikala S, Sodroski J. 2005. Species-specific variation in the B30.2(SPRY) domain of TRIM35α determines the potency of human immunodeficiency virus restriction. J Virol 79:3139–3145. https://doi.org/10.1128/JVI.79.5.3139-3145.2005.
17. Javanbakht H, Yuan W, Yeung DF, Song B, Diaz-Griffero F, Li Y, Li X, Stremlau M, Sodroski J. 2006. Characterization of TRIM35α trimerization and its contribution to human immunodeficiency virus capsid binding. Virology 353:234–246. https://doi.org/10.1016/j.virol.2006.05.017.
18. Ganser-Pornillos BK, Chandrasekaran V, Pornillos O, Sodroski JG, Sundquist WI, Yeager M. 2011. Hexagonal assembly of a restricting TRIM5α protein. Proc Natl Acad Sci U S A 108:5334–5339. https://doi.org/10.1073/pnas.1013426108.
19. Li YL, Chandrasekaran V, Carter SD, Woodward CL, Christensen DE, Dryden KA, Pornillos O, Yeager M, Ganser-Pornillos BK, Jensen GJ, Sundquist WI. 2016. Primate TRIM5 proteins form hexagonal nets on HIV-1 capsids. Elife 5:e16269. https://doi.org/10.7554/elife.16269.
20. Hatzioannou T, Cowan S, Goff SP, Bieniasz PD, Towers GJ. 2003. Restriction of multiple divergent retroviruses by Lv1 and Ref1. EMBO J 22:385–394. https://doi.org/10.1093/emboj/cdg042.
21. Yap MW, Nisole S, Lynch C, Stoye JP. 2004. Trim5α protein restricts both HIV-1 and murine leukemia virus. Proc Natl Acad Sci U S A 101:10786–10791. https://doi.org/10.1073/pnas.0402876101.
22. Perron MJ, Stremlau M, Song B, Ulm W, Mulligan RC, Sodroski J. 2004. TRIM5α mediates the postentry block to N-tropic murine leukemia viruses in human cells. Proc Natl Acad Sci U S A 101:11827–11832. https://doi.org/10.1073/pnas.0403364101.

March 2018 Volume 92 Issue 5 e01541-17 jvi.asm.org
Morger et al. Journal of Virology

23. Satrri J, Campbell EM. 2011. Recent insights into the mechanism and consequences of TRIM5alpha retroviral restriction. AIDS Res Hum Retroviruses 27:231–238. https://doi.org/10.1089/aid.2010.0367.

24. Keckesova Z, Ylilnen LM, Towers GJ. 2004. The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities. Proc Natl Acad Sci U S A 101:10780–10785. https://doi.org/10.1073/pnas.0402474101.

25. Wilson SJ, Webb BL, Maplanka C, Newman RM, Verschoor EJ, Heeney JL, Towers GJ. 2008. Rhesus macaque TRIMs alleles have divergent antiretroviral specificities. J Virol 82:7243–7247. https://doi.org/10.1128/JVI.00307-08.

26. Fletcher AJ, Towers GJ. 2013. Inhibition of retroviral replication by members of the TRIM protein family. Curr Top Microbiol Immunol 371:29–66. https://doi.org/10.1007/978-3-642-37655-5_2.

27. Stremlau M, Perron M, Lee M, Li Y, Song B, Javanbakht H, Diaz-Girrffo F, Anderson DJ, Sundquist WI, Sodroski J. 2006. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc Natl Acad Sci U S A 103:5514–5519. https://doi.org/10.1073/pnas.0509996103.

28. Yap MW, Nisole S, Stoye JP. 2005. A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. Curr Biol 15:73–78. https://doi.org/10.1016/j.cub.2004.12.042.

29. Biris N, Tomasheshvili A, Bhatchantarya A, Diaz-Girffo F, Ivanov DN. 2013. Rhesus monkey Trim5alpha SPRY domain recognizes multiple epitopes that span several capsid monomers on the surface of the HIV-1 mature viral core. J Mol Biol 425:5032–5044. https://doi.org/10.1016/j.jmb.2013.07.025.

30. Owens CM, Song B, Perron MJ, Yang PC, Stremlau M, Sodroski J. 2004. Binding and susceptibility to postentry restriction factors in monkey cells are specified by distinct regions of the human immunodeficiency virus type 1 capsid. J Virol 78:5423–5437. https://doi.org/10.1128/JVI.78.10.5423-5437.2004.

31. Maillard PV, Zoete V, Michielen O, Trono D. 2011. Homology-based identification of capsid determinants that protect HIV-1 from human TRIM5alpha restriction. J Biol Chem 286:8128–8140. https://doi.org/10.1074/jbc.M110.176609.

32. Nomaguchi M, Yokoyama M, Kono K, Nakayama EE, Shioda T, Doi N, Fujwara S, Saito A, Akai H, Miyakawa K, Ryo A, Ode H, Iwatani Y, Miura T, Igarashi T, Sato H, Adachi A. 2013. Generation of rhesus macaque-tropic HIV-1 clones that are resistant to major anti-HIV-1 restriction factors. J Virol 87:11447–11461. https://doi.org/10.1128/JVI.01549-13.

33. Finn AD, Towers GJ. 2012. Structure of the rhesus monkey TRIM5alpha SPRY domain. Biochemistry 51:1466–1476. https://doi.org/10.1021/bi4014962.

34. Schuck P, Trono D. 2007. Production and titration of lentiviral vectors. Current Protoc Hum Genet Chapter 12 Unit 12.10. https://doi.org/10.1002/9780471429059.hg1210s54.

35. Gross I, Hohenberg K, Krausslich HG. 1997. In vitro assembly properties of purified bacterially expressed capsid proteins of human immunodeficiency virus type 1. Eur J Biochem 249:592–600. https://doi.org/10.1111/j.1432-1033.1997.tb04592.x.

36. Velichkova MI, Ivanov DN. 2014. Recognition of the HIV capsid by the TRIM5alpha restriction factor is mediated by a subset of pre-existing conformations of the TRIM5alpha SPRY domain. Biochemistry 53:1466–1476. https://doi.org/10.1021/bi4014962.

37. Wilkie WP, Trono D. 2007. Production and titration of lentiviral vectors. Current Protoc Hum Genet Chapter 12 Unit 12.10. https://doi.org/10.1002/9780471429059.hg1210s54.

38. Breitsprecher D. 2014. Microscale thermophoresis: interaction analysis and beyond. J Mol Struct 1077:101–113. https://doi.org/10.1016/j.molstruc.2014.03.009.

39. Dertinger T, Pachevo C, von der Hocht I, Hartmann R, Gregor I, Enderlein J. 2007. Two-focus fluorescence correlation spectroscopy: a new tool for accurate and absolute diffusion measurements. Chemphyschem 8:443–444. https://doi.org/10.1002/cphc.200600638.

40. Yoo S, Myszka DG, Yeh C, McMurray M, Hill CP, Sundquist WI. 1997. Molecular recognition in the HIV-1 capsid/cyclophilin A complex. J Mol Biol 270:780–795. https://doi.org/10.1006/jmbi.1997.1611.

41. Li X, Yeung DF, Fiegen AM, Sodroski J. 2011. Determinants of the higher order association of the restriction factor Trim5alpha and other tripartite motif (TRIM) proteins. J Biol Chem 286:27959–27970. https://doi.org/10.1074/jbc.M111.260406.

42. Sawyer SL, Wu L, Ememer M, Malik HS. 2005. Positive selection of primate Trim5alpha identifies a critical species-specific retroviral restriction domain. Proc Natl Acad Sci U S A 102:2832–2837. https://doi.org/10.1073/pnas.0409851102.

43. Song B, Javanbakht H, Perron M, Park DH, Stremlau M, Sodroski J. 2005. Retrovirus restriction by Trim5alpha variants from Old World and New World primates. J Virol 79:3930–3937. https://doi.org/10.1128/JVI.79.10.3930-3937.2005.

44. Song B, Gold B, O’Huiggin C, Javanbakht H, Li X, Stremlau M, Winkler D, Cullen M, Sodroski J. 2005. The B30.2(SPRY) domain of the retroviral restriction factor Trim5alpha exhibits lineage-specific length and sequence variation in primates. J Virol 79:6111–6121. https://doi.org/10.1128/JVI.79.10.6111-6121.2005.

45. Kovalsky DB, Ivanov DN. 2014. Recognition of the HIV capsid by the TRIM5alpha restriction factor is mediated by a subset of pre-existing conformations of the TRIM5alpha SPRY domain. Biochemistry 53:1466–1476. https://doi.org/10.1021/bi4014962.

46. Salmen P, Trono D. 2007. Production and titration of lentiviral vectors. Current Protoc Hum Genet Chapter 12 Unit 12.10. https://doi.org/10.1002/9780471429059.hg1210s54.

47. Ganser-Pornillos BK, Cheng A, Yeager M. 2007. Structure of full-length HIV-1 capsid protein. Nature 449:424–427. https://doi.org/10.1038/nature06940.

48. Ganser-Pornillos BK, Cheng A, Yeager M. 2007. Structure of full-length HIV-1 CA: a mosaic for the mature capsid lattice. Cell 131:70–79. https://doi.org/10.1016/j.cell.2007.08.018.

49. del Alamo M, Rivas G, Mateu MG. 2005. Effect of macromolecular crowding agents on human immunodeficiency virus type 1 capsid protein assembly in vitro. J Virol 79:14271–14281. https://doi.org/10.1128/JVI.79.22.14271-14281.2005.